Medifast

MED

Market cap $146M

MED boosts growth efforts with new products, digital tools and an expanded OPTAVIA coaching network.

BALTIMORE--(BUSINESS WIRE)--With more than 90% of U.S. adults classified as metabolically unhealthy1, the silent crisis of metabolic dysfunction continues to escalate. This condition can be linked to a range of challenges, including being overweight and having difficulty maintaining energy, vitality and long-term health and wellbeing. To address this issue, Medifast, the 40+ year old health and wellness company known for its science-backed, coach-guided lifestyle system, is reinforcing its comm.

Medifast (MED) reported earnings 30 days ago. What's next for the stock?

MED is expanding OPTAVIA, digital tools and wellness offerings to drive long-term growth and strengthen customer ties.

MED's second-quarter 2025 earnings and sales decline as active earning OPTAVIA coaches dipped, hit by client acquisition.

Medifast, Inc. (NYSE:MED ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Daniel R. Chard - Executive Chairman & CEO James P.

Medifast (MED) Q2 Revenue Falls 37%

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2025. Second Quarter 2025 Revenue: $105.6 million, with revenue per active earning coach of $4,630 Active Coaches: Independent active earning OPTAVIA coaches of 22,800 Net Income: $2.5 million or $0.22 per diluted share, which includes a gain on investment in LifeMD (Nasdaq: LFMD) c.

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the quarter ended June 30, 2025 on Monday, August 4, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conf.

Initiate Medifast with Strong Buy and $56 PT, citing overlooked operational inflection and coach network momentum driving above-consensus FY26 revenue growth. ASCEND product line and digital engagement tools are key catalysts, improving client retention, coach productivity, and setting the stage for a top line comeback. Valuation is anchored on a conservative 1.3x forward P/S multiple, offering asymmetric risk/reward with tangible execution momentum and significant rerating potential.